A

AnaptysBio
D

ANAB

16.130
USD
-0.75
(-4.44%)
مغلق
حجم التداول
14,548
الربح لكل سهم
-6
العائد الربحي
-
P/E
-3
حجم السوق
490,814,641
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.085
    (-0.48%)
    17.805 USD
    ALNY
    ALNY
    1.73
    (0.65%)
    266.69 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    ESPR
    0.05000
    (2.33%)
    2.20000 USD
    N
    NBIX
    0.840
    (0.58%)
    146.750 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    S
    SRPT
    -0.920
    (-0.79%)
    116.020 USD
    V
    VKTX
    1.170
    (3.56%)
    34.060 USD
    المزيد
الأخبار
المقالات

العنوان: AnaptysBio

القطاع: Healthcare
الصناعة: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).